An initial approach could involve screening for drugs that mimic the function of MAGI3-PDZ1, thereby achieving negative regulation of the MAS-ERK pathway to address Sunitinib resistance in ccRCC patients. This evidence concerns the gene MAS1 and nonpapillary renal cell carcinoma.